Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized induction and maintenance comparisons in newly diagnosed multiple myeloma
2009-010956-93Phase 4Unknown
- Sponsor
- University of Leeds
- Start
- Sep 2009
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of lenalidomide, thalidomide, bortezomib, carfilzomib, vorinostat and 2 more in multiple myeloma (MM) (6 arms), sponsored by University of Leeds. Primary endpoints: Overall survival and Progression-free survival. Status: unknown.
02
Drugs
lenalidomidethalidomidebortezomibcarfilzomibvorinostat
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2009-010956-93.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-010956-93.